Tom Lynch out­lines his come­back strat­e­gy for Bris­tol-My­ers’ bad­ly bruised R&D or­ga­ni­za­tion

Thomas Lynch

When Tom Lynch took the top R&D job at Bris­tol-My­ers Squibb, he got one of the best — and at the same time, one of the hard­est — jobs in biotech.

It was one of the best be­cause Bris­tol-My­ers built what is wide­ly con­sid­ered one of the most in­no­v­a­tive re­search groups for a bio­phar­ma of its size, in a heavy­weight class not known for home­made break­throughs. It was one of the hard­est be­cause the group had just de­railed, giv­ing up its first-place po­si­tion in im­muno-on­col­o­gy in a hard fall on a mis­guid­ed late-stage ef­fort on lung can­cer.

That’s how Lynch end­ed up with the job.

Dur­ing yes­ter­day’s Q1 call with an­a­lysts, Lynch — who made an un­usu­al move from the board to head of R&D — out­lined his strat­e­gy for what comes next. How can Bris­tol-My­ers re­trieve its lead po­si­tion?

As Lynch not­ed to a group that in­clud­ed some ex­pe­ri­enced skep­tics, his board­room po­si­tion gave him a bird’s eye view of the com­pa­ny’s op­er­a­tions. For a first in­ter­view with an­a­lysts, he pro­vid­ed an im­pres­sive, de­tailed strat­e­gy out­line, rec­og­niz­ing the weak­ness­es in Bris­tol-My­ers’ I/O ef­forts and of­fer­ing ways to deal with those weak­ness­es in the clin­ic.

Lynch’s game plan cen­ters on the com­pa­ny’s work on next-gen com­bos, look­ing to build on Op­di­vo (PD-1) and Yer­voy (CT­LA-4) — with all its faults — with new com­bos and less tox­ic al­ter­na­tives now in the clin­ic.

In Lynch’s words, here’s the strat­e­gy:

— (F)irst, ac­cel­er­at­ing the de­liv­ery of our next wave of I-O as­sets like IDO, which we re­cent­ly pre­sent­ed da­ta on at AACR. We’ll al­so be pre­sent­ing ear­ly re­sults for LAG-3, GITR, and the In­cyte IDO at AS­CO this year.

— Sec­ond, un­der­stand­ing the bi­ol­o­gy of I-O re­sis­tance, both in­trin­sic re­sis­tance and ac­quired, and bring­ing a laser-like fo­cus to over­com­ing this. We will fo­cus on ex­pand­ing in­to tu­mor types where I-O hasn’t had a broad im­pact yet, tu­mors like breast can­cer, col­orec­tal can­cer, and prostate can­cer. We will use our next-wave as­sets to cre­ate op­tions for pa­tients who progress on their ini­tial I-O ther­a­py.

— Third, we will con­tin­ue to de­vel­op com­bi­na­tion reg­i­mens, in­clud­ing I-O/I-O com­bi­na­tions, I-O/tar­get­ed com­bi­na­tions, and I-O/chemother­a­py com­bi­na­tions where these make sense.

— And fourth, we will ac­cel­er­ate the de­vel­op­ment of our most promis­ing as­sets in the car­dio­vas­cu­lar, im­muno-sci­ence, and fi­bro­sis pipeline. As [CEO] Gio­van­ni [Caforio] men­tioned, we re­cent­ly pre­sent­ed promis­ing Phase II da­ta on our FGF21 as­set in pa­tients with NASH at the In­ter­na­tion­al Liv­er Con­gress. The re­sults showed an im­prove­ment across mul­ti­ple as­pects of NASH, in­clud­ing a sig­nif­i­cant re­duc­tion in liv­er fat ver­sus place­bo.

He fol­lowed up by cit­ing an ex­pand­ed re­la­tion­ship with Cy­tomX to build a less tox­ic CT­LA-4, a move that could even­tu­al­ly have ma­jor im­pli­ca­tions for con­tenders like As­traZeneca, and all the big ri­vals cur­rent­ly in the mar­ket, from Mer­ck to Roche and Pfiz­er/Mer­ck KGaA. IDO com­bi­na­tions will play a role here as well.

Ge­off Meacham at Bar­clays ob­serves that it seems that the biggest op­por­tu­ni­ty is in “cold tu­mors, breast, ovar­i­an, colon, et cetera. To fol­low up on the ear­li­er com­ment, CT­LA-4 com­bos, do you guys feel, at this point, CT­LA-4 com­bos plus a PD-L1 is go­ing to be a com­po­nent of that?”

Lynch:

So we think we have mul­ti­ple op­por­tu­ni­ties to look at com­bi­na­tions of I-O/I-O agents in these cold tu­mors. We pre­sent­ed da­ta with our IDO as­set, as you men­tioned, and we al­so will be pre­sent­ing ini­tial da­ta at AS­CO this year with our GITR com­pound, which could be the type of agent that might play a role in the cold tu­mor space.

Tim An­der­son at Bern­stein al­so ze­roed in on grow­ing ques­tions about the fu­ture of PD-1, CT­LA-4 com­bos. “A bear’s point of view could say that this fore­tells prob­lems with Yer­voy and Op­di­vo, specif­i­cal­ly in front-line lung.”

Lynch:

I think the first is that again, just em­pha­siz­ing how com­plex and dif­fi­cult a dis­ease lung can­cer is to treat, it’s high­ly un­like­ly that there’s go­ing to be one ap­proach that’s go­ing to fit every pa­tient who presents in first-line. We be­lieve strong­ly that Yer­voy/Op­di­vo is cer­tain­ly one of the op­tions that needs to be pur­sued and de­vel­oped, and we’re look­ing at that in first-line lung can­cer. And we’re al­so look­ing at it in the set­ting of what ap­pro­pri­ate bio­mark­ers might be im­por­tant in eval­u­at­ing the po­ten­tial for this com­bi­na­tion and for re­al­ly all of our drugs in first-line lung can­cer.

Fi­nal­ly, on new R&D in­vest­ments:

“(W)e’ve got to ex­e­cute our pipeline. We’ve got to de­vel­op our next-gen­er­a­tion drugs. And to do that, we’re go­ing to need to in­vest in tu­mor bi­ol­o­gy and trans­la­tion­al med­i­cine as well as da­ta and an­a­lyt­ics.”

So there’s the plan. Tak­ing over at R&D now is like jump­ing on a rolling truck at Bris­tol-My­ers, which spent $5 bil­lion on re­search last year. You can grab the wheel, but then you have to man­age the mo­men­tum. That won’t be easy.

Image courtesy of The Janssen Pharmaceutical Companies of Johnson & Johnson.

Pro­tect­ing the glob­al phar­ma­ceu­ti­cal in­no­va­tion ecosys­tem – what’s at stake?

We are living in a new era of healthcare that is rapidly advancing progress impacting patient outcomes and experiences. We’ve seen a remarkable pace of transformational innovation, applied research, and advanced clinical development over the last decade.

Despite this tremendous progress, there is much more work to be done, and patients are counting on us – now more than ever – to continue that momentum. At the heart of our industry is a focus on developing and delivering medicines for some of the world’s most challenging diseases, including those that have few or no effective treatments today.

Bio­phar­ma's 20 high­est-paid CEOs of 2022, each bring­ing in $20M+ pay­days

Even in a down year for much of the biopharma market, 20 CEOs brought in pay packages valued at more than $20 million, an Endpoints News analysis found.

Endpoints collected data on more than 350 CEO compensation packages, covering a wide range of pharma, biotech, and life sciences companies. All told, the 20 largest earners made over $725 million in 2022 — an average package of $36.4 million. Three brought in paydays over $50 million, and one CEO broke the $100 million mark.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 170,300+ biopharma pros reading Endpoints daily — and it's free.

Mi­rati’s drug sitra­va­tinib flops PhI­II in com­bo with Op­di­vo for cer­tain lung can­cer

Mirati Therapeutics’ path to a second drug approval will likely have to wait. The San Diego biotech company said Wednesday that its investigational lung cancer drug failed a Phase III trial testing it in combination with Bristol Myers Squibb’s Opdivo.

The drug, sitravatinib, and Opdivo weren’t better than the chemo drug docetaxel at keeping patients alive, Mirati said in a press release. The spectrum-selective kinase inhibitor missed the primary goal of overall survival in patients with second- or third-line advanced non-squamous, non-small cell lung cancer.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 170,300+ biopharma pros reading Endpoints daily — and it's free.

End­points 20(+2) un­der 40, 2023; Bio­phar­ma's high­est-paid CEOs; N-of-1 CRISPR sto­ry goes on af­ter tragedy; and more

Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.

We will be off Monday in observance of Memorial Day — and when we get back, it will be a straight march to ASCO, BIO and more. Enjoy the (long) weekend!

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 170,300+ biopharma pros reading Endpoints daily — and it's free.

Rich Horgan (R) with his late brother, Terry

Rich Hor­gan spear­head­ed a gene ther­a­py for his broth­er. The tri­al end­ed in tragedy, but the work con­tin­ues for more pa­tients

Rich Horgan’s quest to create a custom gene therapy for his brother, Terry, ended in tragedy. But Horgan doesn’t believe it’s the end of the story.

Terry, a 27-year-old patient with Duchenne muscular dystrophy, died last October just eight days after receiving the therapy in a clinical trial in which he was the only participant. The case raised questions about the safety of certain gene therapies and what would happen to other drug programs under a nonprofit that Horgan created, called Cure Rare Disease.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 170,300+ biopharma pros reading Endpoints daily — and it's free.

The 20(+2) un­der 40: Your guide to the next gen­er­a­tion of biotech lead­ers

This year’s list of 20 biotech leaders under the age of 40 includes a huge range of ambitions. Some of our honorees are planning to create the next big drug giant. Others are pushing the bounds of AI. One is working to revolutionize TB testing. All are compelling talents who are still young in age, but already far along in achievement.

And, as in years past, we went over. The 20 are actually 22 because of two double profiles that reflect how important teamwork is in the industry. As one of our honorees, Joe Illingworth of DJS Antibodies, told me in our interview, “It takes a village to raise a biotech.”

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 170,300+ biopharma pros reading Endpoints daily — and it's free.

Teresa Bitetti, Takeda's president of the global oncology business unit

Take­da wins pri­or­i­ty re­view for $400M col­orec­tal can­cer drug, li­censed from Hutchmed in Jan­u­ary

Takeda and Hutchmed scored a priority review Thursday afternoon for a colorectal cancer drug, the companies announced.

The experimental drug in question is fruquintinib, previously approved in China in 2018 to treat metastatic colorectal cancer. Takeda and Hutchmed are aiming to bring fruquintinib to the US and other countries outside China in the same indication, and the FDA set its decision date for Nov. 30 of this year.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 170,300+ biopharma pros reading Endpoints daily — and it's free.

Francis deSouza, Illumina CEO (Stefan Wermuth/Bloomberg via Getty Images)

Il­lu­mi­na chair­man oust­ed from board as ac­tivist in­vestor Ic­ahn wins par­tial vic­to­ry

Illumina’s chairman has been ousted from the company’s board, a partial win for activist investor Carl Icahn, who is still likely to put the future leadership and direction of the DNA sequencing giant into question.

The vote to remove chairman John Thompson and put in Andrew Teno was the climax of a proxy fight brought by Icahn after Illumina’s stock slide and decision to buy the cancer-testing company Grail. Illumina said a new chair will be chosen in the coming weeks.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 170,300+ biopharma pros reading Endpoints daily — and it's free.

David Ricks, Eli Lilly CEO (Carolyn Kaster/AP Images)

Lil­ly gears up trio of PhI­II tri­als for its oral GLP-1 amid No­vo Nordisk, Pfiz­er com­pe­ti­tion

As Novo Nordisk and Pfizer disclose some data on their oral weight loss drugs in Phase III and II, respectively, Eli Lilly is beefing up its stance in the obesity field with three late-stage clinical trials of its next-generation GLP-1 agonist orforglipron.

The moves, disclosed in updates to the federal clinical trials database this week, put the Indianapolis drugmaker ahead of Pfizer, whose science chief has said the company will “cherry-pick” which of its mid-stage candidates to take deeper into the clinic after data late this year or early next.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 170,300+ biopharma pros reading Endpoints daily — and it's free.